Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Debt (2018 - 2024)

Neurocrine Biosciences filings provide 6 years of Total Debt readings, the most recent being $122.8 million for Q1 2024.

  • On a quarterly basis, Total Debt changed N/A to $122.8 million in Q1 2024 year-over-year; TTM through Mar 2024 was $122.8 million, a N/A change, with the full-year FY2023 number at $170.1 million, changed 0.41% from a year prior.
  • Total Debt hit $122.8 million in Q1 2024 for Neurocrine Biosciences, down from $170.1 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $425.0 million in Q3 2020 to a low of $122.8 million in Q1 2024.
  • Median Total Debt over the past 4 years was $169.8 million (2023), compared with a mean of $227.0 million.
  • The widest YoY moves for Total Debt: up 0.41% in 2023, down 0.41% in 2023.
  • Neurocrine Biosciences' Total Debt stood at $425.0 million in 2020, then crashed by 60.14% to $169.4 million in 2022, then increased by 0.41% to $170.1 million in 2023, then dropped by 27.81% to $122.8 million in 2024.
  • The last three reported values for Total Debt were $122.8 million (Q1 2024), $170.1 million (Q4 2023), and $169.9 million (Q3 2023) per Business Quant data.